ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 366

Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis

Fatima Alduraibi1, Monica Lawrence2, Larry Borish2 and Adam Carlson3, 1Department of Medicine, University of Virginia Health System, charlottesville, VA, 2Department of Medicine, Division of Allergy and Immunology, University of Virginia Health System, Charlottesville, VA, 3Department of Medicine, Division of Rheumatology, University of Virginia Health System, Charlottesville, VA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoimmunity, CVID, innate immunity, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, October 21, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Common variable immunodeficiency (CVID) is one of the most common symptomatic primary immunodeficiency syndrome with an incidence of ~1 in 25,000 people. CVID is a heterogenous collection of syndromes, which are all characterized by impaired B-cell differentiation, resulting in defective immunoglobulin production and an increased susceptibility to infection. Autoimmune conditions are common in CVID, and the prevalence of autoimmune-associated inflammatory arthritis in patients with CVID is estimated to be around 10%. This study aims to further delineate the features of autoimmune inflammatory arthritis in patients with CVID.

Methods: Using ICD-9 and ICD-10 diagnostic codes, we identified patients with CVID at the University of Virginia from 2007 to 2018. We then reviewed individual charts to identify the patients who met the Revised European Society for Immunodeficiency (ESID) criteria for CVID. From this cohort of patients, we identified those who met the criteria for any one among various autoimmune inflammatory arthropathies. We reviewed the charts of the patients who met all these criteria for details on the treatment and outcomes of both autoimmune inflammatory arthritis and CVID.

Results: A total of 95 patients met the strict criteria for CVID. Of these, six patients (6.31%) were found to have autoimmune inflammatory arthritis; four had rheumatoid arthritis (RA) and two had psoriatic arthritis (PsA). The male-to-female ratio was 1:1. All the patients were non-Hispanic and Caucasian. All the patients were non-Hispanic and Caucasian. The median time between the diagnoses of autoimmune arthritis (median age = 44.5 years) and CVID (median age = 52.5 years) was 129 months (10.7 years). Four patients (66.6%) were initially diagnosed with autoimmune arthritis and had rheumatoid arthritis. Of these, three patients were on methotrexate and two patients were managed with anti-TNF and abatacept. Five patients (83.3 %) received intravenous immunoglobulin (IVIG). Of all of the patients diagnosed with CVID and autoimmune arthritis, none developed a major infection (requiring a lengthy course of antibiotics or hospitalization) while on treatment. Two patients (33.3%) developed other autoimmune diseases, namely, autoimmune thrombocytopenia (ITP) and autoimmune thyroiditis.

Conclusion: Autoimmune inflammatory arthritis was present in 6.31% of the patients in our CVID cohort. Despite the majority of patients being on immunosuppressants and IVIG, none of them developed a major infection during the study. To our knowledge, this study is the first to address the risk of infection in patients with CVID who received immunosuppressants and IVIG. However, the conclusions were limited by the low sample size. Therefore, there is a need for a prospective longitudinal cohort study. Increased vigilance for autoimmune arthritis complications is important as survival outcomes are worse in CVID patients with non-infectious complications. Further evaluation of these patients to understand the mechanism underlying immune dysregulation is essential, as this may promote targeted therapies and improve clinical outcomes.


Disclosure: F. Alduraibi, None; M. Lawrence, None; L. Borish, None; A. Carlson, None.

To cite this abstract in AMA style:

Alduraibi F, Lawrence M, Borish L, Carlson A. Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/infectious-complications-of-immunosuppressive-therapy-in-patients-with-common-variable-immunodeficiency-cvid-and-inflammatory-arthritis/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/infectious-complications-of-immunosuppressive-therapy-in-patients-with-common-variable-immunodeficiency-cvid-and-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.